Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2000

01-08-2000 | Commentary

Where is biological therapy going?

Authors: Hendrik Schulze-Koops, Joachim R Kalden

Published in: Arthritis Research & Therapy | Issue 5/2000

Login to get access

Abstract

The substantial progress in our understanding of molecular and cellular biology has allowed us to design biological therapeutics ('biologicals') with defined targets and effector functions. These biologicals have greatly contributed to our current knowledge of pathogenetic mechanisms in autoimmune diseases. However, although some of the biologicals have been extremely successful in treating the symptoms of chronic inflammation, biological therapy has not yet met the expectations of permanently silencing the chonic immune response. In this commentary we discuss current concepts and future directions of biological therapy, and the potential usefulness of biologicals as a treatment of human autoimmune diseases in appropriate critical applications with the use of suitably designed agents.
Literature
1.
Emmrich F, Schulze-Koops H, Burmester G: Anti-CD4 and other antibodies to cell surface antigens for therapy. In Immunopharmacology of Joints and Connective Tissue. Edited by Davies EM, Dingle JT. London: Academic Press. 1994, 87-117.
2.
Kalden JR, Breedveld FC, Burkhardt H, Burmester GR: . Immunological treatment of autoimmune diseases. Adv Immunol. 1998, 68: 333-418.PubMed
3.
Schulze-Koops H, Burkhardt H, Kalden JR: What we have learned from trials of immunomodulatory agents in RA: future directions. Drugs Today. 1998, 35: 327-351.CrossRef
4.
Wofsy D, Seaman WE: Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985, 161: 378-391.PubMedCrossRef
5.
Waldor MK, Sriram S, Hardy R, Herzenberg LA, Lanier L, Lim M, Steinman L: Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science. 1985, 227: 415-417.PubMedCrossRef
6.
Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG: Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science. 1988, 240: 659-662.PubMedCrossRef
7.
Cobbold SP, Qin SX, Waldmann H: Reprogramming the immune system for tolerance with monoclonal antibodies. Semin Immunol. 1990, 2: 377-387.PubMed
8.
Waldmann H: Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol. 1989, 7: 407-444. 10.1146/annurev.iy.07.040189.002203.PubMedCrossRef
9.
Schulze-Koops H, Davis LS, Haverty TP, Wacholtz MC, Lipsky PE: Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J Rheumatol. 1998, 25: 2065-2076.PubMed
10.
Springer TA: Adhesion receptors of the immune system. Nature. 1990, 346: 425-434. 10.1038/346425a0.PubMedCrossRef
11.
Oppenheimer-Marks N, Davis LS, Bogue DT, Ramberg J, Lipsky PE: Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol . 1991, 147: 2913-2921.PubMed
12.
Kavanaugh AF, Lightfoot E, Lipsky PE, Oppenheimer-Marks N: The role of CD11/CD18 in adhesion and transendothelial migration of T cells: analysis utilizing CD18 deficient T cell clones. J Immunol. 1991, 146: 4149-4156.PubMed
13.
Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994, 37: 992-999.PubMedCrossRef
14.
Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. 1997, 40: 849-853.PubMedCrossRef
15.
Lipsky PE, Davis LS, Cush JJ, Oppenheimer-Marks N: The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol. 1989, 11: 123-162.PubMedCrossRef
16.
Cush JJ, Lipsky PE: The immunopathogenesis of rheumatoid arthritis: the role of cytokines in chronic inflammation. Clin Aspects Autoimmun. 1987, 1: 2-12.
17.
Firestein GS, Paine MM: Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol. 1992, 140: 1309-1314.PubMedPubMedCentral
18.
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet . 1994, 344: 1105-1110. 10.1016/S0140-6736(94)90628-9.PubMedCrossRef
19.
Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995, 34: 334-342.PubMedCrossRef
20.
Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P: Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000, 27: 841-850.PubMed
21.
Sander O, Rau R, van Riel P, van der Putte L, Hasler F, Baudin M, Ludin E, MsAuliffe T, Dickinson S, Kahny MR: Neutralization of TNF by lenercept (TNFR55-IgG1, Ro 45/-2081) in patients with rheumatoid arthritis treated for three months: results of a European phase II trial. Arthritis Rheum. 1996, 39: S242-
22.
Maini RN, Taylor PC: Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000, 51: 207-229. 10.1146/annurev.med.51.1.207.PubMedCrossRef
23.
Charles PJ, Elliott MJ, Feldmann M: Development of anti-ds DNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNF alpha. EULAR J. 1995, 24: B114-
24.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet . 1999, 354: 1932-1999. 10.1016/S0140-6736(99)05246-0.PubMedCrossRef
25.
Adorini L, Guery JC, Trembleau S: Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? . Autoimmunity. 1996, 23: 53-68.PubMedCrossRef
26.
Saoudi A, Kuhn J, Huygen K, de Kozak Y, Velu T, Goldman M, Druet P, Bellon B: TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol . 1993, 23: 3096-3103.PubMedCrossRef
27.
Fowell D, Mason D: Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med. 1993, 177: 627-636.PubMedCrossRef
28.
van der Veen RC, Stohlman SA: Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL-10. J Neuroimmunol. 1993, 48: 213-220. 10.1016/0165-5728(93)90194-4.PubMedCrossRef
29.
Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS: Elevated Th1-or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol. 1995, 155: 5029-5037.PubMed
30.
Rocken M, Racke M, Shevach EM: IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today. 1996, 17: 225-231. 10.1016/0167-5699(96)80556-1.PubMedCrossRef
31.
Skapenko A, Wendler J, Lipsky PE, Kalden JR, Schulze-Koops H: Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol. 1999, 163: 491-499.PubMed
32.
Sloan-Lancaster J, Allen PM: Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol. 1996, 14: 1-27. 10.1146/annurev.immunol.14.1.1.PubMedCrossRef
33.
Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, Martin R, Utz U, Karin N, Mitchell D: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 1996, 379: 343-346. 10.1038/379343a0.PubMedCrossRef
Metadata
Title
Where is biological therapy going?
Authors
Hendrik Schulze-Koops
Joachim R Kalden
Publication date
01-08-2000
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar108

Other articles of this Issue 5/2000

Arthritis Research & Therapy 5/2000 Go to the issue

Review

Fibroblast biology Synovial fibroblasts in rheumatoid arthritis: leading role or chorus line?

Research article

Cytokine, activation marker, and chemokine receptor expression by individual CD4+ memory T cells in rheumatoid arthritis synovium

Review

Fibroblast biology: Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis

Review

Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs

Review

Fibroblast biology Signals targeting the synovial fibroblast in arthritis

Review

Endothelial cells and immune cell migration
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits